pharmaphorum May 10, 2022
Roche has elevated a longstanding alliance with Finland’s Kaiku Health focusing on digital patient monitoring and management (DPMM) to the level of a strategic partnership.
The two companies have been working together since 2019 on digital health interventions to provide support to people with cancer, focusing initially on tools for patients undergoing cancer immunotherapy.
The initial partnership led to a pilot of personalised support modules for people being treated with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) – alone and in combination with other drugs – in Germany, Switzerland and Finland.
Results of the pilot in 45 patients with non-small cell lung cancer (NSCLC) treated with Tecentriq with and without chemotherapy were published in 2020. The data showed that patients as well...